Questcor (QCOR) Sees Multi-Billion Market Opportunity for Acthar in MS, IS, NS Patients
Tweet Send to a FriendGet Alerts QCOR Hot Sheet
Price: $47.46 +3.33%
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: +40.7%
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: +40.7%
Trade QCOR Now!
Questcor (Nasdaq: QCOR) is trading higher Wednesday following presentation of data from the company for its Acthar drug at the Jefferies 2012 Global Healthcare Conference in New York.
Data show that paid vials for nephrotic syndrome, (NS) were 100 to 110 in May, from 94 in April, multiple sclerosis (MS) at 360 to 370 in May, from 339 the prior month, and infantile spasms (IS) to a range of 30 to 35, from 31 in April. Overall, shipped vials in May expected at 1,560, from 1,350 in April.
Total market opportunity for Acthar is $3 billion.
Estimated annualized net sales run rate for Acthar is the following:
Data show that paid vials for nephrotic syndrome, (NS) were 100 to 110 in May, from 94 in April, multiple sclerosis (MS) at 360 to 370 in May, from 339 the prior month, and infantile spasms (IS) to a range of 30 to 35, from 31 in April. Overall, shipped vials in May expected at 1,560, from 1,350 in April.
Total market opportunity for Acthar is $3 billion.
Estimated annualized net sales run rate for Acthar is the following:
- MS - $160 million to $175 million
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Depomed (DEPO) Reports Submission of ANDA for Generic Zipsor
- VIVUS (VVUS) Reports Statistically Significant Data from STENDRA Study
- Bristol-Myers (BMY), AstraZeneca (AZN) SAVOR-TIMI-53 Misses Primary Efficacy Endpoint in Phase 4
Create E-mail Alert Related Categories
Corporate News, FDARelated Entities
Jefferies & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
